News Sentiment

RPRX sentiment intelligence

Royalty Pharma Plc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 74 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 58.18 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+3.1% over one week, +9.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

SEB Asset Management AB Invests $12.97 Million in Royalty Pharma PLC $RPRX

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 3.1% Price confirming higher
Trend fit Trend active 9.9% over four weeks
Fair value 75.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 51
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 20
Market source 10
simplywall.st 7
MarketBeat 6
TradingView 5
GlobeNewswire 2
MT Newswires 2
Quiver Quantitative 1

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 19
Deals and strategy 5
Balance sheet 4
Capital return 3
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 74
Stock Titan Direct company coverage

Royalty Pharma (RPRX) EVP Marshall Urist sells 9,098 shares under 10b5-1 plan

Royalty Pharma EVP Marshall Urist sold 9,098 Class A Ordinary Shares at a weighted average price of $55.1843 per share, totaling over $502,000, under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. Following this transaction, Urist directly holds 9,099 share

Tone
Negative 39/100
Event
Market update
Published
25 Jun 2026 21:41
Source
Stock Titan
TradingView Direct company coverage

Royalty Pharma Plc Class A Actuals & Estimates (NASDAQ:RPRX)

This article provides an overview of Royalty Pharma plc (NASDAQ: RPRX) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial results, such as recent earnings per share and revenue, and key metrics like market ca

Tone
Positive 67/100
Event
Earnings
Published
25 Jun 2026 18:09
Source
TradingView
Investing.com Australia Direct company coverage

Form 144 Royalty Pharma plc For: 24 June By Investing.com

This article from Investing.com is a brief report about Royalty Pharma plc's Form 144 filing for June 24. It includes the ticker symbol RPRX which showed a slight increase of 0.76%. The content consists mostly of market data, indices, commodity prices, and other financial perform

Tone
Neutral 50/100
Event
Macro sensitivity
Published
25 Jun 2026 02:41
Source
Investing.com Australia
Stock Titan Direct company coverage

Marshall Urist sells shares at Royalty Pharma plc (NASDAQ: RPRX)

Marshall Urist, an insider at Royalty Pharma plc (NASDAQ: RPRX), reported selling 13,684 shares on May 14, 2026, for $726,137.82 and another 13,684 shares on May 20, 2026, for $721,837.21. These transactions were disclosed in a Form 144 SEC filing, which also noted an Equity Perf

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

[SCHEDULE 13D/A] Royalty Pharma plc Amended Major Shareholder Report

Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini have filed Amendment No. 8 to their Schedule 13D for Royalty Pharma plc, indicating their beneficial ownership has decreased to 4.8% of outstanding Class A shares, below the 5% threshold. This fi

Tone
Negative 40/100
Event
Market update
Published
16 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Royalty Pharma (RPRX) director Carole Ho awarded 4,545 restricted shares

Royalty Pharma plc director Carole Ho was awarded 4,545 Class A Ordinary Shares in the form of restricted stock units as compensation. The award, valued at $0.00 per share, is set to vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting.

Tone
Positive 64/100
Event
Market update
Published
08 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Royalty Pharma (RPRX) director awarded 4,545 restricted stock units in equity grant

Royalty Pharma director Gregory Norden was awarded 4,545 Class A Ordinary Shares in restricted stock units (RSUs) on June 5, 2026, as an equity grant under the company’s 2020 Independent Director Equity Incentive Plan. The RSUs have a grant price of $0.00 per share and are set to

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Royalty Pharma (RPRX) director receives 4,545 share unit award

Royalty Pharma plc director Elizabeth H. Weatherman was granted an equity award of 4,545 restricted stock units, which are Class A Ordinary Shares. This compensation-related award, at no cash cost, will vest 100% on the earlier of one year from the grant date or the next annual s

Tone
Neutral 50/100
Event
Balance sheet
Published
08 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Director Ted Love receives 4,545 RSUs at Royalty Pharma (RPRX)

Royalty Pharma director Ted W. Love received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units (RSUs). These RSUs, granted under the company's 2020 Independent Director Equity Incentive Plan, generally vest 100% on the earlier of one year from

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Director at Royalty Pharma (RPRX) receives 4,545 restricted stock units grant

Royalty Pharma plc director David C. Hodgson received a grant of 4,545 restricted stock units (RSUs) tied to Class A ordinary shares as equity compensation. These RSUs, awarded under the company's 2020 Independent Director Equity Incentive Plan, will vest 100% on the earlier of o

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Royalty Pharma (RPRX) director awarded 4,545 RSUs under 2020 equity plan

Royalty Pharma plc (RPRX) director Vlad Coric was granted 4,545 Restricted Stock Units (RSUs) at no cost under the company's 2020 Independent Director Equity Incentive Plan. These RSUs will vest 100% on the earlier of one year from the grant date or the next annual shareholder me

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Royalty Pharma (RPRX) awards 4,545 RSUs to board director

Royalty Pharma (RPRX) reported that its director, Catherine M. Engelbert, received an award of 4,545 Class A Ordinary Shares in the form of restricted stock units (RSUs). This award was granted under the company’s 2020 Independent Director Equity Incentive Plan at no cash cost to

Tone
Neutral 50/100
Event
Balance sheet
Published
08 Jun 2026 20:09
Source
Stock Titan
Stock Titan Direct company coverage

Royalty Pharma (RPRX) director Bonnie Bassler awarded 4,545 RSUs, raising holdings to 78,492 shares

Royalty Pharma (RPRX) director Bonnie L. Bassler was granted 4,545 restricted stock units (RSUs) as part of her compensation, increasing her direct holdings to 78,492 Class A Ordinary Shares. This award, made under the company's 2020 Independent Director Equity Incentive Plan, ve

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 20:09
Source
Stock Titan
TradingView Direct company coverage

Cash from operating activities of Royalty Pharma Plc Class A – XETR:RPD

The article focuses on the "Cash from operating activities" for Royalty Pharma Plc Class A, traded on XETRA under the symbol RPD. It presents a data table showing the period, value, change, and percentage change for this financial metric. The content underscores the financial ove

Tone
Neutral 50/100
Event
Balance sheet
Published
06 Jun 2026 23:10
Source
TradingView
Stock Titan Direct company coverage

Royalty Pharma (RPRX) shareholders back directors, pay and share issuance powers at 2026 AGM

Royalty Pharma plc shareholders approved all proposals at its 2026 Annual General Meeting, with a strong quorum of 88.08% voting power. Key approvals included the election of all nine director nominees, executive compensation on a non-binding basis, and the ratification and re-ap

Tone
Positive 59/100
Event
Market update
Published
04 Jun 2026 20:10
Source
Stock Titan
ChartMill Direct company coverage

RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)

This article provides a comprehensive overview of ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) stock, including its current price, performance metrics, and key statistics such as market cap, P/E ratio, and dividend yield. It also covers technical and fundamental analysis ratings from C

Tone
Positive 75/100
Event
Capital return
Published
29 May 2026 17:40
Source
ChartMill
Investing.com Direct company coverage

Royalty Pharma EVP & CFO Coyne sells $3.48 million in shares

Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 64,399 Class A Ordinary Shares for approximately $3.48 million on May 26, 2026, executed via a pre-arranged 10b5-1 trading plan. This sale occurred near the stock's 52-week high, with the company showcasing strong Q1 2026

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 21:08
Source
Investing.com